Skeletal Disease Drug Development Pipeline Review, 2017

Thursday, July 13, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 12, 2017 /PRNewswire/ --

SummaryThis report provides an overview of the skeletal disease pipeline

landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA).OA is one of the most common forms
of arthritis. It is a chronic condition in which the cartilage breaks down. There are a total of 116 products in development for this indication, by 87 companies and 8 academic institutions. Key companies operating in this pipeline space include Arcarios, Nordic Bioscience, Rottapharm Biotech and the University of Toledo.Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. There are a total of 112 products in development for this indication, by 80 companies and 16 academic institutions. Key companies operating in this pipeline space include Max Biopharma, Omeros, Affilogic laboratories, Amgen and the University of Wisconsin Madison.Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. There are a total of 13 products in development for this indication, by ten companies. Key companies operating in this pipeline space include Amgen and Ipsen.The predominant targets within OA are prostaglandin G/H synthases 1 and 2, although a wide range of targets, including extracellular matrix-organizing proteins and interleukins, are being studied. Likewise, within both osteoporosis and the post-menopausal subtype, a broad range of molecular targets are being studied. The targets being most frequently studied are the parathyroid hormone receptor, tumor necrosis factor ligand superfamily member 11 and sclerostin.Scope- Which companies are the most active within the pipeline for osteoporosis and OA therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of osteoporosis and OA therapeutics?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: http://www.reportlinker.com/p04978348/Skeletal-Disease-Drug-Development-Pipeline-Review.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/skeletal-disease-drug-development-pipeline-review-2017-300487210.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook